$217 Million is the total value of Qiming U.S. Ventures Management, LLC's 6 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2021 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VENTYX BIOSCIENCES INC | 11 | Q2 2024 | 37.8% |
| KEZAR LIFE SCIENCES INC | 11 | Q2 2024 | 12.9% |
| ICOSAVAX INC | 9 | Q4 2023 | 50.7% |
| JASPER THERAPEUTICS INC | 9 | Q4 2023 | 21.1% |
| HILLEVAX INC | 9 | Q2 2024 | 15.4% |
| ELEVATION ONCOLOGY INC | 9 | Q4 2023 | 6.6% |
| TALARIS THERAPEUTICS INC | 8 | Q3 2023 | 27.1% |
| KORRO BIO INC | 3 | Q2 2024 | 36.9% |
| TOURMALINE BIO INC | 3 | Q2 2024 | 18.9% |
| JASPER THERAPEUTICS INC | 2 | Q2 2024 | 40.1% |
View Qiming U.S. Ventures Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-13 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-04-25 |
| 13F-HR | 2023-01-24 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-07-22 |
View Qiming U.S. Ventures Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.